14 New Weight Loss Drugs Are in the Pipeline. Here's What the Research Actually Shows.
From triple-receptor agonists to a once-daily pill, the obesity drug pipeline just got very crowded.
Good — I now have solid sourced material. Let me write the article.
GoodRx published a roundup this week counting 14 new weight-loss drugs currently working their way through the pipeline. Fourteen. That number would have been unthinkable five years ago. Here's what the research actually says about the most advanced contenders — and what it means if you're already on a GLP-1 or thinking about starting one.
Why the Pipeline Exploded
The short answer: Ozempic and Wegovy proved the concept. Once GLP-1 receptor agonists showed that a drug could produce meaningful, sustained weight loss, every major pharma company started asking what came next.
MedlinePlus describes obesity as a disease — not a character flaw — that raises risk for a cascade of other conditions. That framing shifted how regulators, payers, and researchers treat the category. When you combine clinical urgency with a proven mechanism, R&D budgets follow.
A 2025 systematic review in Pharmacology Reviews catalogued the emerging pharmacotherapies in this space, and a separate pipeline overview in International Journal of Obesity mapped out where the most promising candidates sit in development. The short version: we're moving from single-receptor drugs to drugs that hit two, three, or even four targets at once.
Retatrutide: The Triple-Threat Already in Phase 3
Retatrutide (Eli Lilly) is probably the most-watched drug in the pipeline right now. It hits GLP-1, GIP, and glucagon receptors simultaneously — making it a triple agonist where Mounjaro and Zepbound are dual agonists.
A Phase 2 trial published in The New England Journal of Medicine reported results that turned heads across the field. The drug is now in active Phase 3 testing: ClinicalTrials.gov currently shows a recruiting Phase 3 study (NCT07357415) evaluating retatrutide in adults with obesity or overweight without type 2 diabetes, running for roughly 113 weeks. There's also a Phase 3 trial (NCT07035093) looking at whether it helps chronic low back pain in people with obesity — a sign researchers are already probing benefits beyond weight.
CagriSema: Novo Nordisk's Combination Shot
CagriSema pairs semaglutide (the active ingredient in Wegovy) with cagrilintide, an amylin analogue. The idea is that two hormonal pathways are better than one.
Two large Phase 3 trials — REDEFINE 1 and REDEFINE 2, both published in The New England Journal of Medicine in August 2025 — tested the combination in adults with obesity and in adults with obesity plus type 2 diabetes, respectively. Novo Nordisk is now running a Phase 3 trial in children and adolescents (NCT07253285) and a Phase 1 study (NCT07527195) specifically examining what the drug does to muscle health during weight loss — a question a lot of current GLP-1 users are already asking.
Orforglipron: The Pill Version of GLP-1
Every injectable GLP-1 works great — if you're okay with weekly injections. Orforglipron (Eli Lilly) is a small-molecule, once-daily oral GLP-1 receptor agonist. No injection, no refrigeration, no reconstitution.
A Phase 2 trial in NEJM showed meaningful weight loss in adults with obesity. More recently, the ATTAIN-1 trial results published in NEJM in November 2025 added to that evidence base. A meta-analysis in Metabolism comparing orforglipron and danuglipron (another oral small-molecule GLP-1) found the class showed both efficacy and a manageable safety profile across randomized controlled trials — though GI side effects remain a factor, as they do with injectables. Managed Healthcare Executive noted in March 2026 that orforglipron could reshape the entire GLP-1 market if it clears FDA review — primarily because a pill removes the biggest barrier to access for many people.
Amycretin: A New Class Entirely
The farthest out but worth watching: amycretin is a first-in-class drug that combines GLP-1 and amylin receptor agonism in a single molecule. A Phase 1 first-in-human trial published in The Lancet in July 2025 reported on its safety, tolerability, and early pharmacodynamics. It's early — but the amylin pathway is the same one CagriSema is targeting with cagrilintide, and researchers are clearly betting it adds something meaningful on top of GLP-1 alone.
Meanwhile, Deloitte's May 2026 analysis flagged that the boom in obesity R&D is driving pharma's best pipeline returns in years — but also warned the industry could face a "bubble" effect if too many drugs chase the same patients.
What This Means for You
- More options are coming, but not tomorrow. Phase 3 trials run for two or more years, and FDA review adds more time on top. The drugs getting headlines today are likely 2027–2029 approvals at the earliest.
- The pill question is real. If injections are your main objection to starting a GLP-1, orforglipron's progress is worth tracking — ask your prescriber what they're hearing.
- Muscle health is getting attention. The fact that Novo Nordisk is running a dedicated trial on CagriSema's effect on muscle is a signal that the field is taking lean-mass preservation seriously. That's good news for anyone worried about what weight loss does to their body composition.
Not medical advice. Talk to your prescriber about your specific situation, history, and which — if any — of these options might be right for you.
